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Populations are aging, and many people over the age of 50 live with multiple 
long-term conditions and take multiple medications. Medication is the single 
most common healthcare intervention and generates the third highest cost 
of health expenditure. Up to 11% of all unplanned hospital admissions are 
attributable to medicines related harm.a The European Union has identified 
the reduction of avoidable harm in healthcare as a key priority. Over the last 15 
years, in reports such as To Err is Human, countries have raised patient safety 
as an opportunity to reduce harm. Building on this, both Choosing Wisely,  
Free from Harm and the Patient Safety 2030 report suggest that this could 
be approached by developing a holistic systematic approach that extends 
across the professional, cultural, technological and procedural boundaries.b,c,d
The SIMPATHY (Stimulating Innovation Management of Polypharmacy  
and Adherence in The Elderly) consortium have explored how healthcare 
management programmes can be implemented to improve medication safety 
and prevent patient harm by addressing the appropriate use of multiple  
medications (polypharmacy). Fundamental to these programmes is the 
principle that providers work in partnership with patients to enable shared 
decision making regarding medication, which improves patient adherence 
and medicines related outcomes. 
This report sets out the case for prioritising working together now to address 
inappropriate medication use over the next decade, to ensure the quality, 
economic and political systems are put in place to improve medication safety 
for patients. There are encouraging signs of the increasing recognition of these 
challenges, and the timeliness of this report. In March 2017, the World Health 
Organization (WHO) launched a global patient challenge to address medication 
safety, with polypharmacy as a flagship element. A special interest group was 
launched by the International Foundation on Integrated Care in May 2017.
First and foremost, the priority for polypharmacy management has to be 
about the quality and safety of patient care. It is essentially done within the 
economic resources available and enabled by political support.
We commend the recommendations of this report to you and call for your 
support in tackling together the important issues in delivering appropriate 
management of polypharmacy.
Liam J Donaldson
Envoy for Patient Safety
World Health Organization 
Geneva, Switzerland
Edward T Kelley
Director, Service Delivery and Safety
World Health Organization  
Geneva, Switzerland
a. Kongkaew C, Hann M, Mandal J, Williams SD, Metcalfe D, Noyce PR, Ashcroft DM. Risk factors for hospital 
admissions associated with adverse drug events. Pharmacotherapy. 2013;33(8):827-37. doi:10.1002/phar.1287
b. Kohn LT, Corrigan JM, Donaldson MS, Eds. To err is human - building a safer health system. Washington, D.C. 
National Academy Press; 2000. ISBN: 0-309-06837-1
c. Malhotra A, Maughan D, Ansell J, Lehman R, Henderson A, Gray M, Stephenson T, Bailey S. Choosing Wisely  
in the UK: the Academy of Medical Royal Colleges’ initiative to reduce the harms  
of too much medicine. BMJ. 2015;350:h2308. doi: 10.1136/bmj.h2308.
d. Yu A, Flott K, Chainani N, Fontana G, Darzi A. Patient Safety 2030. London: NIHR Imperial Patient Safety 
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All of us have a role to play in leadership to drive change 
to manage polypharmacy, regardless of the position we 
hold and whether we are patient organisations, gov-
ernment bodies, clinicians, managers or policymakers. 
Inappropriate polypharmacy and medicines adherence 
in the elderly is one of the most significant public health 
challenges of the current age. This burden is set to 
increase as the population ages and more people suffer 
from multiple long-term conditions. There remains a lack 
of evidence-based solutions, as both medical research 
and healthcare delivery models have focused on single 
disease interventions. This challenge, and the limited 
range of solutions, have significant implications for how 
healthcare resource is used to address inappropriate 
polypharmacy. However, with up to 11% of unplanned 
hospital admissions being attributable to harm from med-
icines, and over 70% of these being due to elderly patients 
on multiple medicines there are significant opportunities 
to reduce this burden by timely and effective interventions.1 
 
The Institute of Medicine report, Responsible use of Medi-
cines demonstrates that 0.3% of the global health budget 
could be saved by managing polypharmacy appropriately.2 
The report identifies key areas of focus which include using 
risk stratification to identify vulnerable patients and a more 
collaborative role for pharmacists, physicians and patients.
Facing the challenge of reducing patient harm, the Euro-
pean Union (EU) issued a public health call to identify, de-
velop and implement innovative solutions that can be im-
plemented at scale to address key problems. Stimulating 
Innovation Management of Polypharmacy and Adherence 
in the Elderly (SIMPATHY) is one of the funded projects to 
deliver tools to implement polypharmacy management 
programmes throughout the EU in the context of quality, 
economic and political factors.
The SIMPATHY case studies, benchmarking survey  
and literature review demonstrate that there are some 
effective polypharmacy management programmes in  
the EU, but that they are too few in number. The project 
also demonstrates that patients believe inappropriate 
polypharmacy is an important issue to address.
This report calls for EU countries to work together in a 
focused way to manage and prevent inappropriate 
polypharmacy, and improve medicines adherence, 
through the use of a change management approach  
that is coordinated and collaborative in order to deliver 
better patient outcomes through the following six key 
recommendations:
Adopting these recommendations will help prepare EU 
countries for the WHO global  patient safety challenge  
to improve medication safety, of which polypharmacy  
is an essential element.
Use a systems approach that has multidisciplinary   
clinical and policy leadership
Nurture a culture that encourages and prioritises  
the safety and quality of prescribing 
Ensure that patients are integral to the decisions  
made about their medicines and are empowered  
and supported to do so 
Use data to drive change 
Adopt an evidenced based approach with a bias 
towards action 
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The proportion of the global population over 65 years old 
will increase from 11% in 2010 to 22% in 2050. In Europe, 
advances in healthcare, education and socio-economic 
circumstance mean that in most countries people can 
now expect to live beyond the age of 80. However, evi-
dence shows that the average healthy life years (HLY) for 
EU citizens is only 61 years meaning that many people are 
living for around twenty years in sub-optimal health.
Multimorbidity is defined by the World Health Organiza-
tion as the co-occurrence of two or more chronic medical 
conditions in one person.3 Patients with multimorbidity 
may require medicines to treat each condition, which 
can lead to polypharmacy. Currently around 50 million 
EU citizens are estimated to have multimorbidity. Most of 
them are 65 years and over, and this number is expected 
to continue to increase.4 
 
Linking clinical and prescribing data, from a European 
country, has shown that 20.8% of people with two chron-
ic conditions were taking between four and nine med-
icines daily. 10.1% were taking over ten medicines, and 
those patients taking the most medicines are the oldest.5 
Data also shows that multimorbidity and polypharmacy 
affects adults up to ten years earlier in deprived commu-
nities. The burden of multiple diseases can have a com-
bined effect on physical health, the quality of day-to-day 
living and mental health.6 
The burden of multiple treatments can be just as prob-
lematic, causing frequent healthcare contacts and an 
increasing likelihood of medicine side effects, adverse 
drug reactions and interactions.
Non-adherence to prescribed medicines is a major 
public health issue, intricately related to multimorbidity 
and polypharmacy. Research suggests that between 
50% and 80% of patients with chronic conditions may 
be non-adherent, depending on the clinical condition 
being studied. Non-adherence has been estimated to be 
responsible for 48% of asthma deaths, an 80% increased 
risk of death in diabetes and a 3.8-fold increased risk of 
death following a heart attack.7 It has been estimated 
that non-adherence to medicines costs the European 
Union 125 billion euros annually.8
 
Polypharmacy
There are a number of different definitions of 
polypharmacy but it is generally understood as 
the concurrent use of multiple medicines by one 
individual. It can be therapeutically beneficial when 
appropriate or inappropriate when not. 
• Appropriate polypharmacy is defined as 
prescribing for an individual for complex 
conditions or for multiple conditions in 
circumstances where medicines use has  
been optimised and where the medicines  
are prescribed according to best evidence.
• Inappropriate polypharmacy is defined 
as the prescribing of multiple medicines 
inappropriately, or where the intended  
benefit of the medication is not realised.
• Polypharmacy management is a whole 
systems approach which optimises the  
care of multimorbid patients through 
maximising benefit while reducing the  
risks of inappropriate polypharmacy.
Non-adherence 
There are two overlapping categories of 
non-adherence to medicines.
• Intentional non-adherence, where the 
individual decides not to follow the treatment 
recommendations perhaps because of 
concerns about the value or effectiveness 
of medicines, their side effects, and the 
inconvenience of taking the medicines at the 
prescribed times and frequency.
• Unintentional non-adherence, where the 
individual wants to follow the treatment 
recommendations but is prevented from 
doing so by practical barriers which include 
cognitive problems, poor organisational skills, 
polypharmacy and difficulty accessing medicines.
Introduction
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The European Innovation Partnership on Active and 
Healthy Ageing has a target to increase the average 
healthy lifespan of citizens by two years by 2020.9 
The Partnership is seeking to identify and share good 
practice and drive research and innovation. One of the 
Partnership’s action groups, ‘Prescribing and Adherence 
to Medical Plans’, includes a focus on multimorbidity  
and polypharmacy.
The 2012 Institute for Healthcare Informatics report,  
Advancing the responsible use of medicines, identified 
several opportunities to save healthcare spending 
through more responsible use of medicines worldwide.2 
Using multiple international datasets, it was estimated 
that inappropriate polypharmacy contributes to 4% of 
the avoidable costs due to suboptimal medicine use. A 
total of 0.3% of global total health expenditure, or 18 billion 
US dollars worldwide, could be avoided by managing 
polypharmacy correctly. Specific recommendations in this 
report were to: invest in medical audits targeting elderly 
patients; develop the role of pharmacists to help patients 
manage their own medicines; support pharmacist collab-
oration with physicians for medication reviews; prepare a 
targeted medicines management plan and to encourage 
use of risk stratification processes to identify patients.
Many healthcare organisations have sought to address 
the problem of fragmented delivery of health and social 
services, through the more coordinated approach, of 
integrated care. Collaboration in this way is an essential 
aspect of addressing inappropriate polypharmacy.  
Building on the benefits of integrated care there is now 
an additional focus on population and public health in 
order to minimise or prevent inappropriate polypharmacy 
in the first place. 
The SIMPATHY project was awarded funding on an 
EU public health call to support the use of innovative, 
coordinated and comprehensive community based 
prevention to optimise the care of multimorbid patients. 
The project demonstrates the importance of a systems 
approach to developing polypharmacy management 
through understanding the requirements of the individual 
patient, carers and organisations, and the political and 
economic environment. 
About this handbook
Funded by the EU Health Programme (2014-2020) the 
SIMPATHY project’s goal is to stimulate and support 
innovation across the EU in the management of polyp-
harmacy and adherence with specific focus on address-
ing inappropriate polypharmacy in the context of quality, 
economic and political factors.
Focussing on change management, this handbook high-
lights the approaches that can help health systems to 
deliver effective polypharmacy management in order to 
help address the issues caused by multiple medicine use 
for multiple medical conditions. Included are a range of 
examples of good practice and tools from local, regional 
and national programmes. 
The content is informed by the findings of the SIMPATHY 
case studies,10 analysis of SIMPATHY change management 
tools,11 SIMPATHY literature review and benchmarking 
survey,12 and SIMPATHY Delphi study.13
SIMPATHY confirms the findings of Advancing the  
responsible use of medicines,14 that there are currently  
too few polypharmacy management programmes. There 
is a consensus among all stakeholder groups for the need 
to address the issue of inappropriate polypharmacy. There 
is a recognition of the quality of existing programmes, but 
significant concerns expressed regarding the challenge 
of how to initiate polypharmacy management in countries, 
where services do not exist, and how to expand where 
services are concentrated in a small area. The project 
demonstrates how change management can be used  
as a successful approach to help initiate and implement 














In depth studies to understand 
current practices showcasing 
different approaches to  
polypharmacy management  
in the EU.
Benchmarking
Europe wide regional and 
local benchmarking survey 
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tools to support innovation in 







Management of polypharmacy  
is an essential element of patient 
safety in an integrated care 
setting making a significant 
contribution to well-being
Prevention of harm due to 
medicines can reduce demands 
on the healthcare system 
reducing threats to service 
sustainability
Demographic changes are 
driving up public awareness 
of polypharmacy issues, 
demanding a response from 
politicians and policymakers
1. Use a systems approach that has multidisciplinary 
clinical and policy leadership
2. Nurture a culture that encourages and prioritises 
the safety and quality of prescribing 
3. Ensure that patients are integral to the decisions 
made about their medicines and are empowered  
and supported to do so 
4. Use data to drive change
5. Adopt an evidence based approach with a bias 
towards action 
6. Utilise, develop and share tools to support 
implementation
THE SIMPATHY PROJECT


























05-09 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15+
MORE MEDICINES
MORE FRAILTY
10 OR MORE 
MEDICINES
FRAILTY




PERCENTAGE OF PEOPLE BY AGE GROUP 
ON MULTIPLE MEDICINES
Num. medicines
FRAILTY AND THE NUMBER OF MEDICINES
The case for appropriate 
polypharmacy management 
Complex care
The shift in demographics to an aging population with 
increasing multimorbidity leads to increasing complexity 
in care. Health inequalities can add to this complexity, 
where long-term illness can present 10-15 years earlier  
in the most deprived groups.
Quality 
A growing population with multimorbidity using multiple 
medicines (polypharmacy) for long periods of their lives 
are at increased risk of adverse events, error and harm.
Economic
Increasing demand on constrained health budgets 
creates the need for change to ensure that medicines 
and healthcare resources are used optimally.
Politics and policy
Multimorbidity and polypharmacy are a widespread 
and growing challenge, adversely affecting the quality 
of life of EU citizens and increasing pressures on health 
systems. The solutions require political and policy 




There are many factors that are creating favorable 
circumstances to address the polypharmacy challenge. 
Resources are constrained and under increasing demand 
as people live longer with multiple morbidities. There  
is a focus on improving safety and quality of healthcare 
and avoiding harm. Workforce pressures mean that 
healthcare professionals and policymakers are more 
open to multidisciplinary working.
Polypharmacy is a growing problem as population 
longevity and the incidence of multimorbidity increase. 
Although not exclusive to the elderly, polypharmacy in 
older people presents particular challenges. Physiologi-
cal decline and frailty, combined with inappropriate poly-
pharmacy, increases the potential for harm in older peo-
ple. This is compounded by the risks of non-adherence to 
complex treatment regimens.15 These factors combine to 
increase the likelihood of morbidity, unplanned admission, 
readmission and prolonged length of stay in hospital. 
Modern prescribing is largely based on single disease 
evidence-based guidance which does not generally take 
account of multimorbidity, despite this being the norm in 
those over 65 years.6 In contrast, polypharmacy manage-
ment aims to optimise outcomes by ensuring that through-
out life people are prescribed the safest and most effective 
combination of medicines to manage their multimorbidity 
and to maintain well-being for as long as possible. 
Caring for patients with multimorbidity treated with 
polypharmacy is a widespread and increasingly common 
global challenge. Polypharmacy management involves 
complex decision making and requires the combined 
knowledge of physicians, pharmacists and nurses sup-
ported by informed patient interaction. 
Good communication and accurate sharing of informa-
tion is essential, facilitated by information technology 
systems that support cohesiveness and integration 
across health and care systems. Re-design of services 
to proactively cope with an increased clinical workload 
related to polypharmacy can relieve pressures on servic-
es as a whole. Appropriate polypharmacy avoids unnec-
essary work for all health and care professionals and 
carers at the same time as improving patient outcomes. 
Consequent improved adherence with medication can 
also contribute to improve outcomes.
 
Given this evidence, the case for effective polypharmacy 
management is quite clear, but in a complex healthcare 
setting with many competing priorities it is useful to 
outline the quality, economic and political reasons why 
this should be prioritised within every EU country’s health 
policies and plans for active and healthy aging. 
The SIMPATHY benchmarking study set out to identify 
the status of polypharmacy management across the EU, 
gathering more than 1,000 responses from a spectrum of 
stakeholders across 26 EU countries.12 Although responses 
were mainly from clinical practitioners, 10% of responses 
were from patients. 
Across the EU a lack of understanding was shown 
regarding the issue of polypharmacy, in terms of its defi-
nition, and any consistent framework against which to 
measure progress. This finding was not confined to any 
one stakeholder group but applied equally to clinical and 
non-clinical stakeholders, and patients.
This survey sought to benchmark key indicators of perfor-
mance relevant to effective polypharmacy management. 
The findings clearly illustrated that there is an absence of 
knowledge and meaningful metrics across all countries and 
stakeholders. Of particular note was the almost complete 
lack of awareness of the health economics related to appro-
priate medicines use. However, more than 60% of respond-
ents thought that health economic data would be useful. 
The existence of programmes to manage polypharmacy, 
where more than 10% of the country respondents indicated 
this, were restricted to the UK, Sweden, Portugal, Spain, 
Germany and the Netherlands. The activities of the reported 
programmes were: prescription reviews (83%); treatment 
reviews (77%) and clinical medication reviews (71%).
Quality
People with multimorbidities, taking multiple medications 
(polypharmacy), are at increased risk of potentially avoid-
able medicine related issues. All medicines are associated 
with a level of risk and it is estimated that worldwide, 3-6% 
of all hospital admissions are attributed to medicines, and 
figures ranging from 2-19% have been recorded in the USA 
with studies in the UK reporting up to 11%.1,16-18 
Over half of medicines-related hospital admissions in the 
over 65s on multiple medications are preventable, with four 
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groups accounting for 50% of these (antiplatelets, diuretics, 
anticoagulants and non-steroidal anti-inflammatory drugs).1
Prescribing errors are common in all healthcare settings 
and another major cause of harm. The UK General  
Medical Council in 2012 reported that one in 20 prescriptions 
in primary care contained an error with a higher prevalence 
associated with prescriptions for the elderly and those 
taking 10 or more medicines.19 In hospital prescribing, errors 
are also a common occurrence, affecting 50% of hospital 
admissions.20 When patients transfer between health and 
social care settings evidence shows that 30% to 70% of 
patients experience an error or unintentional change to 
their medicines.21 Taking multiple medicines, long term, 
presents difficulties for individuals and carers managing 
complex medicine regimens with evidence that between 
30-50% of these medicines are not taken as prescribed.22
The SIMPATHY literature review confirmed that there is 
evidence to support the principle that medication reviews 
reduce inappropriate polypharmacy.23 Recent research 
has also begun to show improvement in outcomes due 
to polypharmacy management, including a reduction in 
hospital admissions.24 The SIMPATHY literature review 
identified that there are guidance documents available 
relating to the management of polypharmacy in only 5 of 
the 28 EU countries, with only the guidance documents 
from Scotland, the Netherlands and Germany scoring the 
maximum on the AGREE II-GRS criteria for quality.25 
 
There remains an evidence gap, whilst research catches up 
with this fundamental shift in healthcare priority. Safety is a 
major concern in modern healthcare and addressing issues 
related to inappropriate polypharmacy should form part of 
this. The literature review supports the principle that it is 
important to adopt an evidence based approach, but with a 
bias towards action where the evidence is limited. It should 
also be recognised that there is further emerging evidence 
to support polypharmacy management research, that is in 
process, and yet to publish.
Economic
The demand for health and social care is increasing 
globally in response to demographic shift, pharmaceu-
tical and technological advances. This creates budg-
etary pressure between the healthcare needs and the 
resources available in most EU countries. Constrained 
budgets call for the prudent use of resources to gain 
the best possible outcomes from investment. Evidence 
based approaches that deliver clinical and cost-effective 
care are of interest to all governments and this has been 
increasingly supported by policy documents.26
 
Throughout Europe, 16% of total government expenditure 
is dedicated to healthcare, ranging from 6% in Cyprus to 
22% in Switzerland.4 After inpatient and outpatient care, 
pharmaceuticals represent the third largest expenditure in 
healthcare and accounted for around a sixth of total health 
expenditure in 2014, not taking into account spending in 
hospitals.27 In 2014 the total pharmaceuticals bill across the 
EU was 200 billion euros and the average spend per head of 
population was 402 euros with wide variation between coun-
tries, from 201 euros in Denmark to 551 euros in Germany.
Medicines are one of the highest costs in EU healthcare 
systems and are consequently one of the most commonly 
targeted areas for efficiency savings. Post financial crisis, 
between 2009 and 2014, expenditure on pharmaceuticals 
dropped by 1.1% in real terms on average in the EU, mainly 
triggered by cuts in public spending. However, there are 
signs that spending is increasing again in some countries 
due to the steep growth in spending on high cost medicines 
to treat, for example, hepatitis C or oncological conditions.27 
Effective polypharmacy management can deliver im-
proved safety and health outcomes plus economic ben-
efits. Avoiding harm from adverse drug events improves 
patient outcomes in addition to delivering economic 
benefit through fewer hospital admissions, readmissions 
and reduced length of hospital stay. Economic modelling 
has found there may be cost savings related to optimis-
ing the number and combination of medicines, avoiding 
waste, reducing utilisation of acute healthcare services 
and freeing health service capacity. 
The SIMPATHY Delphi survey failed to report consensus 
about the importance of economic data but highlighted  
a lack of understanding that better care can lead to  
economic benefit with comments such as, “economic  
outcomes are not the main goal. Our priority and main 
goals are the patient safety and efficacy, and efficiency”.13 
The SIMPATHY case studies provide examples of good 
practice that have demonstrated cost savings relating  
to medicines costs and reduced hospital admission, 




Improved quality leading to economic benefits
In a randomised controlled trial in Sweden, clinical 
pharmacists performed comprehensive medication 
reviews on elderly hospitalised patients. Patients 
who received a medication review had 16% fewer 
hospital visits and 47% fewer visits to the emergency 
department within a 12-month follow-up period 
compared to usual care. Medication-related 
readmissions were even reduced by 80%. After 
inclusion of the intervention costs, the total hospital 
based healthcare costs per patient in the intervention 
group was approximately 200 euros lower than in 
the control group. The researchers concluded that, 
if implemented on a population basis, the addition of 
clinical pharmacists to healthcare teams would lead to 
major reductions in morbidity and healthcare costs.
Scotland
Economic benefits of implementing good practice
The implementation of the Scottish Polypharmacy 
Management Programme was underpinned by 
detailed economic analysis. The data demonstrates 
notable savings, even when taking into account the 
cost of reviews: 
Range of estimates of savings from polypharmacy reviews
Unit cost/saving 
Scotland







Number of patients with high risk medicines 40,585 64,729
Cost estimates based on savings per case p.a GBP GBP M GBP M
1 Med stopped; 6 repeats; 1 yr; unit cost GBP 9.87 9.87 2.4 3.8
2 Meds stopped; 6 repeats; 1 yr; unit cost GBP 9.87 19.74 4.8 7.7
Lower estimate of value of medications stopped 66 2.7 4.3
Base-case: change medication only 90 3.7 5.8
Upper estimate: change medication + switching  
to cost effective + cost avoidance measures
155 6.3 10.0
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Italy
Political support helping spread change 
In Italy, the SIMPATHY project stimulated collaboration 
among the many different stakeholders of the regional 
health system in the Campania region, raising aware-
ness about the implications of polypharmacy in the 
Regional Health System.
The Campania region is integrated in the national network 
for the internationalisation of regional health systems, 
therefore Campania stakeholders involved in the  
SIMPATHY project had the opportunity to share their expe-
rience. The results of the project were shared with other 
Italian regions, as well as with the Italian Ministry of Health. 
This, in turn, has fostered  the exchange of good practices 
and contributed to the national plan for chronic diseases.
Sharing the SIMPATHY experience within the national 
network facilitated the identification of a shared priority 
to respond to a research call by the Ministry of Health 
leading to an inter-regional project on the management 
of multimorbidity in community-dwelling older adults, 
with a focus on integrated polypharmacy and reha-
bilitative robotics. For this project Campania, Liguria, 
Piemonte and Calabria along with the Ministry of Health 
co-financed a total budget of 4.2 million euros.
Politics and policy
The politics of policy making is an important aspect to  
consider. The political case for more effective polypharmacy 
management is to improve patient outcomes and patient 
well-being of the citizen as they age. This is set out in the 
EU led European Innovation Programme on Active and 
Healthy Aging (EIP AHA).9 This should improve the out-
comes for patients by improving quality and patient safety 
and deliver economic benefits. Innovative models that 
deliver this care through multiprofessional working can 
also help address the capacity of the traditional workforce 
models that are under extra pressure, due to challenges of 
an aging population with increasing multiple morbidities.
 
Kingdon suggests that there is usually a window of 
opportunity for concepts to be accepted and adopted 
politically which are dependent on three components 
being essential: problem recognition; generation of policy 
proposals; and political events.28 For addressing poly-
pharmacy, the window is open and policies are being 
driven that acknowledge the problems, as governments 
seek to improve the health of their populations with 
resources that have competing demands.
In addition to establishing integrated care there is a call 
to look at population care systems that aim to address 
the wide range of influences affecting health, as many 
health problems are preventable.29 For example, although 
there may be a focus on care of the elderly, in reality, 29% 
of the people likely to have multiple morbidities and are 
under 65 years of age, and come from the most deprived 
communities.6 Reflecting this, polypharmacy management 
must be considered for whole populations. Since the pub-
lication of Choosing Wisely many policy documents have 
raised awareness of using resources wisely, and also about 
the importance of the greater role of the patient in decision 
making about their healthcare, including, medication.26
Whilst awareness of the benefits of polypharmacy manage-
ment is a growing, there is a need identified through both 
the SIMPATHY benchmarking and Delphi surveys to increase 
understanding about the benefits of effective polypharmacy 
management across the EU.12,13 Further change is needed to 
raise awareness, to share and scale up good practice. 
Political support across EU countries can facilitate  
implementation of effective polypharmacy management to 
improve health and well-being throughout life and protect 
independence into older age. The political work is not sole-
ly policy-focused. Nurturing deep change in how health 
professionals, policymakers and patients think about, and 
practice medication safety in general, and polypharma-
cy in particular will generate some resistance no matter 
how compelling is the evidentiary-based case. Everyone 
involved will have to re-order priorities and adapt to new, 
unfamiliar and sometimes even uncomfortable ways of 
interacting with each other. Helping people through that 
process is a different kind of work than convincing them  
of the merits of poplypharmacy management, but just as 
essential to policy and implementation success. SIMPATHY 
consortium engaged with the expertise of Marty Linsky in 
addressing political challenges and recordings are offered 




Using policy to drive polypharmacy management 
In Scotland, the existence of clinical leaders with a 
national policy role meant that effective polypharmacy 
management developed regionally in some National 
Health Service boards, could be scaled up through the 
development of a polypharmacy guidance document 
that was supported through an official Chief Executive 





















 NHS Ayrshire and Arran   NHS Borders   NHS Dumfries and Galloway    NHS Fife   NHS Forth Valley   NHS Grampian   NHS Greater Glasgow and Clyde   
 NHS Highland   NHS Lanarkshire   NHS Lothian   NHS Orkney   NHS Shetland   NHS Tayside   NHS Western Isles
Scotland has a well developed polypharmacy review programme.  
The National Polypharmacy Guidance (2015) has been adopted by all 14 health 
boards (100%), with each board developing plans to identify priority patients who 
have potentially inappropriate elements to their polypharmacy, and to implement 
reviews for those patients at highest risk of harm.  
Introduction of mobile app has sustained acceleration.
The sense of urgency was created by 
highlighting that current prescribing of 
medicines was not fit to meet the chang-
ing needs of an aging population with 
increasing multiple long-term conditions, 
particularly in terms of the increasing po-
tential to cause harm and risk to financial 
sustainability of prescribing patterns.
Building the guiding coalition came 
from linking the pioneering work by 
NHS Highland and NHS Tayside with 
key clinical policymakers. Crucial was 
the early engagement of clinicians and 
operational leaders.
Formation of the strategic vision came 
through refinement of the adoptive work 
by NHS Lothian and the Scottish Govern-
ment. Policy leadership was essential 
with clinical leadership to meet the 
needs of patients and prescribers.
Enlisting the volunteer army was 
exemplified by NHS Greater Glasgow and 
Clyde, who serve 25% of the Scottish 
population, and were able to implement 
the Polypharmacy Guidance at scale 
through using established means 
of implementation through practice 
pharmacist networks working with GPs.
Removing barriers to implementation 
included successful addition of a con-
tractual requirement for GPs, and rec-
ognising the potential role of Pharmacist 
non-medical prescribers. Design delivery 
process to enable care to be integrated 
into existing patient pathway.
Generating short term wins includes the 
evidence that on average one or two 
medicines were stopped at each polyp-
harmacy review. There are approximately 
12,000 polypharmacy reviews every year 
in Scotland.  
Of those patients  identified to be at high 
risk of hospital admission, pilot work 
suggested a 40% reduction in hospital ad-
missions following a polypharmacy review. 
Further reduction in high risk medication 
related issues is expected from roll out.
Management of polypharmacy using 
the Scottish multi-disciplinary approach 
helped develop therapeutic partnerships 
between doctors and pharmacists in 
primary care that has been integrated 
into national program of work.
http://www.polypharmacy.scot.nhs.uk/
All 14 Scottish Health Boards use the 
Polypharmacy Guidance.
€20 m
is being invested to increase the number 
of pharmacists working in GP practices 
Mobile App for clinicians developed
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Germany
Political influence driving systems change
Since October 2016 a uniform standard medication 
chart has been introduced for mandatory use by all 
doctors and pharmacists. Every person with three or 
more medicines is entitled to receive such a medica-
tion chart on paper, equipped with a QR-code, so that 
pharmacists and doctors can digitally read, update 
and exchange information on medicines. This initiative 
has been supported and driven by the Federal Ministry 
of Health and has been agreed by all relevant stake-
holders on the federal level. The standard medication 
chart is part of the e-Health Law and insures that all 
prescribed medicines data are documented in this 
digital format. It can be printed out in doctors’ offices 
in the consultation as a paper version for the patient. 
The governmental aims are clear and input is strong 
in this field considering that Germany has a system of 
sharing powers between the government, the health 
insurances as self-regulated non-profit organisations 
and the health professional entities. 
Now GPs receive a small fee for service remuneration 
to incentivise the new practice. By 2018 the interim 
solution of using a paper medication chart kept with 
the patient will be replaced by the electronic health 
card issued by the health insurances.
Poland
Policy driving change
The Polish Ministry of Health has created a group 
whose aim is to develop a model and strategy on poly-
pharmacy management in the elderly. The group was 
established on August 27th, 2015 by the Minister of the 
Health Directive. It includes representatives  
of the National Health Fund, the Ministry of Health, 
pharmacists, lawyers, pharmaceutical inspectors  
and pharmaceutical societies. The team’s task is  
“to develop a project of pharmaceutical care which 




Policy commitment across the healthcare system
Optimising the health benefits from medicines is an  
important enabler of active and healthy aging in 
Northern Ireland. In March 2016 the Minister of Health 
announced the publication of a new strategy ‘The  
Medicines Optimisation Quality Framework’ to help peo-
ple to gain the best possible outcomes from medicines.
In addition there was a formal commitment to imple-
menting the Framework through an innovation and 
change programme which seeks to develop, test and 
scale up best practices to support a national medi-
cines optimisation model. In the next three years there 
will be a focus on the needs of older people specifical-
ly relating to pharmacy roles, services and smart tech-
nologies which support appropriate polypharmacy 
and better adherence. 
Outputs include a national medicines optimisation 
model to support appropriate polypharmacy and bet-
ter adherence and a Medicines Optimisation Innova-
tion Centre to support research, service development 
and knowledge sharing nationally and internationally.
Catalan Health Plan 2010-2015: Guiding policy for all health programmes in Catalonia
Strategic work line: A system oriented toward patients with chronic disease
Programme for the prevention and care of chronic disease (PPAC) 2011-2014: Working group 
implemented to meet Health Plan goals
Rational drug use. Medication management in the complex chronic patient: reconciliation, 
revision, deprescription and adherence: Specific clinical practice recommendation
Catalonia























Preparing for change in 
polypharmacy management
Systems thinking 
Polypharmacy management touches multiple aspects  
of health and care systems and is ideally team-based 
and patient-centred. Embedding polypharmacy  
management into integrated care initiatives will help  
create synergies with ongoing activities that also  
aim to prevent inappropriate polypharmacy. 
Strategies for change management 
Polypharmacy management initiatives are complex and 
require strong leadership and management. Employing a 
change management strategy when designing a poly-
pharmacy management initiative can help maximise the 
odds of successful implementation. 
Organisational culture 
Assessing organisational culture and working to create 
an environment that values teamwork, innovation and 
risk taking will help ensure polypharmacy initiatives are 
successful and sustainable. Organisations should foster 
openness to discussion of harm caused by medicines 
and a willingness to work collaboratively with patients  
to improve outcomes with medicines. 
Patient-centred 
Empowering patients to be involved with the medication 
review process and decision making about their med-
icines will lead to coproduction in the management of 
polypharmacy. From the patient perspective, this will 
address “What matters to me?”. 
SIMPATHY
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Preparing for change in polypharmacy
 
Anyone can exercise leadership in driving change in how 
we address effective polypharmacy management. This is 
possible wherever you work in the health and care system, 
or even if you are outside the system as a patient or an 
organisation that acts as an advocate for patients and car-
ers. The evidence for the need to address polypharmacy  
is compelling, but the challenge of leading change goes 
beyond the evidence to the politics and the culture of  
organisations. This will include policymakers, health pro-
fessionals and managers as well as carers and patient  
advocates. As discussed earlier, often the window of 
opportunity to ensure a change is implemented is small28, 
with the three components being essential: problem recog-
nition; generation of policy proposals; and political events. 
Currently, healthcare resources are under constraint. 
There are workforce issues and challenges of supporting 
an aging population, but there is the need to  improve qual-
ity and outcomes for patients whilst preventing harm.
 
Leadership and the solutions to facilitate success need 
to consider the system in which they are working. Not 
the technical solutions to the problem alone, but under-
standing the changes, pressures and conflicts that might 
need to be addressed to deliver the solution. Solutions 
therefore need to be adaptive and open to tackling any 
conflicts that might arise.
Systems approach in health and care
A systems approach has been defined as “an operating 
mechanism where the sub-parts work jointly towards 
achieving an outcome, and the success of the system is 
dependent upon this collaboration. In patient safety, these 
sub-parts include provider organisations across different 
care settings, regulators, policymakers, and patients”.30,31 
It is important that all stakeholders understand and agree 
the outcomes to be achieved. In the case of polypharmacy 
management, the goal of a systems approach is the optimal 
and sustainable use of medicines in patients with multi-
morbidity, supporting them to live active and healthy lives. 
There is no one blueprint for implementing complex initia-
tives, and a systems approach prevents an overly narrow 
view to a particular problem.31 The Scottish polypharmacy 
programme used a systems approach in the selection 
of a diverse group of stakeholders, with representation 
across different care settings to form the membership  
of a group to develop a national policy and guidance  
for its implementation.32
 
A systems approach has been used by organisations 
such as the WHO, Institute of Healthcare Improvement 
and Institute of Medicine to address complex issues such 
as tobacco control, obesity prevention, or expansion of 
antiretroviral treatment.33-36
The use of a systems approach to polypharmacy man-
agement is supported by both the SIMPATHY case studies 
and the Delphi survey, where there was strong agreement 
that polypharmacy management initiatives should include 
a broad range of stakeholders and be implemented 
across care settings and boundaries.13 
An important first step in applying systems thinking to 
polypharmacy management is to consider the build-
ing blocks of the existing healthcare service. The WHO 
describes six building blocks that make up a complete 
healthcare system. Here we describe how these building 
blocks can be adapted to polypharmacy management, 
developing from the lessons learned from the SIMPATHY 
case studies:10 
 
1. Service delivery: how does introducing polypharmacy 
management affect existing practice and other services? 
2. Health workforce: does polypharmacy management 
involve new roles and responsibilities and do they  
require training? 
Application of systems approach 
Process mapping
When Northern Ireland set out to enact the priorities  
outlined in the National Service Framework for 
Older People, one early step they took was to 
conduct process mapping with a multidisciplinary 
team including managers, pharmacists, and phy-
sicians. Process mapping is a set of tools that can 
help clarify processes and identify bottlenecks of 
inefficient steps within a system. As a result, they 
gained consensus and a clear vision of where their 
medicines optimisation efforts should focus.
































Funding of new  
permanent positions,  
pay for performance
3. Health information: is individual and population level 
data related to polypharmacy management available  
for all healthcare professionals?
4. Medical technologies: what disease-specific clinical 
practice guidelines are professionals using and how  
does this affect polypharmacy management? 
5. Health financing: are reimbursement and payment 
schemes aligned with the goals of polypharmacy  
management? 
6. Leadership and governance: do existing legislation  
and policies support implementation of polypharmacy 
management?
The example from Uppsala, Sweden is shown above. 
Health systems are dynamic and change constantly, with 
feedback loops that positively and negatively affect both, 
the intervention and its effects. One practical implication 
of this is that managers and policymakers should be  
prepared for an iterative process of implementation and 
evaluation. SIMPATHY demonstrates that this was the 
case in Scotland, where polypharmacy guidance was 
launched nationally, but after observing the real-world 
effects of the policy on physicians, pharmacists, and their 
patients, substantial changes were made to the guidance. 
In particular, the review process and the target population 
for review were both adapted to help implementation.
THE UPPSALA (SWEDEN) CASE STUDY 











Improving the health  
of people and populations
(morbidity, mortality and  
quality of life)
Systems complexity may influence resistance to change. 
The competing interests of different professionals who 
have a stake in managing polypharmacy, particularly those 
of physicians and pharmacists, can be a particular chal-
lenge in designing innovative polypharmacy management 
initiatives, especially if there is a change in the work un-
dertaken across professional boundaries. This barrier was 
reported multiple times throughout the SIMPATHY case 
studies,10 and the SIMPATHY PESTEL and SWOT analyses.11
Integrated care recognises the need to create linkages 
between different components of the healthcare delivery 
system taking a holistic view of patient care. Integrated care 
is an important principle to consider in discussions of health 
system reforms, especially when referring to those with 
complex needs, such as older patients and those with multi-
morbidity who are at risk of inappropriate polypharmacy.37
The overarching goals of integrated care are closely 
aligned with the end goals of polypharmacy management. 
This can place polypharmacy initiatives within the context 
of wider health systems planning and facilitates creating 
synergies between health policy initiatives. These goals 
can be summarised as the triple aim (diagram above) 
of improving: patient experience; population health and 
the cost-effectiveness of care systems.38 The patient 
experience is central, a fact emphasised in the WHO 
global strategy on people-centred and integrated health 
services.39 A patient perspective is captured by, my care 
is planned with people who work together to understand 
me and my carer(s), put me in control, co-ordinate and 
delivery services to achieve my best outcomes.40
The focus on patient-centred care is also reflective of opin-
ions of key stakeholders both within the SIMPATHY case 
studies and confirmed by the Delphi survey, where patient 
health outcomes were consistently cited as a primary  
motivator for addressing polypharmacy management.10,13
Although the concept of integrated care is receiving more 
attention, the role of the pharmacist has not always been 
addressed within this context.41 There is good evidence 
of the benefit of pharmacist involvement in medicines 
management, and more recently there have been calls to 
include pharmacists in integrated care teams which close-
ly resembles the primary care polypharmacy management 
model in Scotland, demonstrated in SIMPATHY.41,42
Polypharmacy management should be addressed in all 
care settings, even though primary care may be the main 
location for delivery of the programme. Examples of this 
from SIMPATHY can be seen in the Northern Ireland con-
sultant clinical pharmacist model in intermediate care, 
the Swedish hospital ward based model, or the Catalan 
multidisciplinary management of older patients in acute 
geriatric units and nursing homes.43-45 The latter has demon-
strated positive effects on hospital readmissions, detection 
of adverse drug events, and the quality of prescribing.
Italy
Systems approach to healthcare
The involvement of Campania in the SIMPATHY project 
raised the urgency to measure the impact of hospital 
admissions on polypharmacy, through the FRIENDD 
study (Drugs Reviewed Together: Empowerment In 
Different Specialties). Medical specialists, pharma-
cists and clinical pharmacologists took part in this 
study aiming to test and implement in a real-world 
setting what had been learnt from SIMPATHY on 
polypharmacy management across whole systems. 
The activity performed both a retrospective and pro-
spective analysis aiming to minimise drug interac-
tions in the therapy prescribed at hospital discharge. 
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the potential implementation of a polypharmacy manage-
ment initiative, a pharmacist leader in Greece identified 
that, “we need a step by step approach”.10
 
A change management strategy does not in itself 
guarantee success, but it can diminish the potential for 
failure. Literature provides different change management 
models from different disciplines including business, 
psychology, and sociology, with a handful coming directly 
from healthcare.47 Application of key change manage-
ment models is an important aspect of SIMPATHY.11
Accounting for culture
Underlying all of these models, systems thinking, inte-
grated care and change management, is culture. Culture 
in terms of healthcare is used to capture what it is like 
to work in or receive care from an organisation. It is not 
about appropriate polypharmacy management and 
improved quality of life for patients, but about who we are 
as people. Organisational culture is complex, and affects 
all of the building blocks within the healthcare system. 
It includes the values, assumptions, and beliefs held by 
those within the organisation or, more simply put, ‘culture 
is the way we do things around here’.48,49 
The way we do things influences not only how things 
are currently done, but also the likelihood that a newly 
introduced initiative will fail or succeed. Culture can help 
or hinder the implementation of a new innovation like 
polypharmacy management. In fact, failure to account 
for organisational culture is one of the main reasons cited 
when evaluating why planned change initiatives are not 
able to overcome barriers.
Not only should the culture of the health system as a whole be 
considered, but also cultural norms within given professions. 
The results from the SIMPATHY Delphi study support 
this understanding of organisational culture. There was 
strong agreement that, ‘prior to implementation of poly-
pharmacy management, the culture of the organisation 
should be assessed for both strengths and potential 
barriers to implementation’.13 
 
There were also a number of examples from the SIMPATHY 
cases studies, where culture acted as either a facilitator 
or barrier, both at the system and individual level. From a 
Strategies for change management 
Skilfully employing a change management strategy can 
maximise the odds of successful implementation.46 
Throughout the SIMPATHY case studies, sites with suc-
cessful polypharmacy management initiatives were able 
to point to a specific change management strategy. Pro-
grammes with a systems approach enabled overview of 
development and implementation by a range of stakehold-
ers. If a strategy was not explicitly mentioned, elements of 
change management could still be identified throughout 
the development and implementation process. In coun-
tries without programmes, there was a recognised need to 
manage change in a systematic manner. When discussing 
Catalonia 
Delivering a systems approach to healthcare
Service delivery: All patients meeting criteria for the 
designation of ‘complex chronic patient’ are required 
to have their medicines reviewed. To facilitate this, 
patients meeting the criteria are flagged in the shared 
electronic medical record and physicians review their 
medication list at least once a year. Electronic medical 
records are available in all public health care institu-
tions, facilitating the implementation of this initiative. In 
addition, e-prescription is deployed in full in Catalonia.
Health workforce: At least one physician in every 
primary care centre in Catalonia has received training 
developed jointly by the Agency for Health Quality and 
Assessment of Catalonia, the Catalan Health Service 
and the Catalan Institute of Health. The training is 
case-based covering medicine reconciliation during 
care transitions and conducting medication reviews in 
complex chronic patients. Guidelines have also been 
developed by the Catalan Health Service to assist 
physicians with the management of polypharmacy 
and adherence in the primary care setting. 
 
Health information: Multiple population level health 
indicators are currently available that relate to poly-
pharmacy, although indicators of adherence are 
not as clearly defined or captured. Members of the 
public (including health professionals) can make 
specific data requests for research.
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systems perspective, Northern Ireland described itself as 
‘outwardly-focused’ with a ‘keen interest’ in work being done 
on quality and safety throughout the United Kingdom.10 
Likewise, a hospital Chief Executive Officer in Catalonia, 
Spain described his job as ‘managing innovation’ and that 
the institution had “a culture, a way of doing things that 
greatly facilitates the implementation of these [polypharmacy 
management] programmes”. These are both places where a 
polypharmacy management initiative had been successfully 
implemented within a hospital and care home setting. 
In contrast countries without a polypharmacy initiative, like, 
Greece, Poland, and Portugal, a lack of culture support-
ing teamwork and multidisciplinary teams was identified 
as a primary barrier to polypharmacy management. For 
example, a comment made by a geriatrician was “Only they 
[geriatricians] are qualified enough to coordinate treatment 
of patients with multimorbidities and polypharmacy”, illus-
trating the types of professional-centric views that might 
prohibit implementation of a true multidisciplinary team.10 
Successful implementation would require consideration  
of how to overcome such barriers and attitudes. 
As with change management and systems thinking, there 
are multiple tools and frameworks available to help diag-
nose and change organisational culture and it may be ap-
propriate to do this in parallel with patient safety culture.46 
Patient centered
 
Empowering patients and their carers to be involved with the 
medication review process and decision making about their 
medicines will lead to co-production in the management 
of polypharmacy. This will address ‘What matters to me?’. 
This is important as we know that half of the patients taking 
four or more medicines do not take them as prescribed.3 As 
discussed previously, this can lead to patient harm, where 
non-adherence to prescribed medicines is a major public 
health issue, that is intricately related to multimorbidity and 
polypharmacy. Research suggests that between 50% and 
80% of patients with chronic conditions may be non-ad-
herent, depending on the clinical condition being studied. 
Non-adherence has been estimated to be responsible for 
48% of asthma deaths, an 80% increased risk of death in 
diabetes and a 3.8-fold increased risk of death following a 
heart attack.7 It has been estimated that non-adherence to 
medicines costs the EU 125 billion euros annually.8 By asking 
patients ‘What matters to me?’, patients are able to engage 
in prioritisation and decisions about their medicines.  Pa-
tients should be made aware that they can apply the same 
reasoning and principles when deciding to take medicines 
that are either over the counter or prescribed.
 
Raising patient awareness about the problems of polyp-
harmacy and non-adherence, and how to prevent harm 
from medication related side effects is essential. Patients 
should hold a record of medication that they take and 
share at each care interface to allow clinicians to con-
sider the impact of additional medication, or stopping 
treatment. This can be in either paper or electronic form 
so that it is accessible for all patients.
 
Patients need to be provided with information, and tools 
need to be developed that enable patients to ask ques-
tions and understand how to make decisions regarding the 
management of their long-term conditions. Information 
should be consistent across all parts of the healthcare 
system. Patients should have access to mobile apps and 
tools that help them understand appropriate polypharma-
cy and enable them to be active participants in medication 
reviews. An example of a patient card, known as sick day 
rule guidance is shown below, which is also available on a 
patient polypharmacy app where the patient and clinician 
can agree tailored guidance for the individual.
Ten per cent of the respondents in the SIMPATHY bench-
marking survey were patients, and they felt that polyp-
harmacy reviews were important.12 Patients have a key 
role through patient organisations to ensure that they 
have access to these services. Building on recommen-
dations of reports such as Choosing Wisely suggest joint 
decision making with patients, is important.26
 
In the Scottish Polypharmacy guidance there are 7 key steps 
that have been designed to be used by both the patient and 
the healthcare professionals when making decisions about 
medicines both at initiation of prescribing and at review.
These are described in the bullets below:
Step 1: What matters to the patient?
Step 2: Identify essential drug therapy.
Step 3: Does the patient take unnecessary drug therapy?
Step 4: Are therapeutic objectives being achieved?
Step 5: Is the patient at risk of side effects or suffers 
actual side effects?
Step 6: Is drug therapy cost-effective? 
Step 7: Is the patient willing and able to take drug  
therapy as intended?  












The selection of a change management model appropri-
ate to a polypharmacy management initiative is essential. 
The Kotter 8-steps change management model presents 
a recognisable framework to which most stakeholders 
can relate to, and it has broad applicability.
Getting ready for change
The current situation can be assessed utilising the SWOT 
and PESTEL analysis and this can inform strategic plans. 
Identification of key stakeholders and assessment of the 
economic benefits can be used to establish the sense of 
urgency and influence the implementation of a polyphar-
macy management programme.
Implementing change
The vision should set out clearly the need for the change 
and the goal of change. Clinical and policy leadership is 
essential to remove potential barriers and there should 
be a focus on education and the development of guid-
ance documents for use in multiprofessional teams. 
Spreading and sustaining change
Data and indicators can be used to help spread and 
sustain change. Polypharmacy management should be 
integrated into routine practice so that additional work-
load is not created. There may be the option to support 
this through the use of contractual arrangements.
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The EU spends almost a sixth of its healthcare budget 
on medicines and so dealing with the challenge of an 
aging population with increasing numbers of multiple 
morbidities that require additional numbers of medicines 
is a challenge that needs to be addressed as a matter of 
urgency. This issue is likely to be a challenge beyond the 
current economic crisis as not only is it a patient safety 
issue but also one that needs addressing as a public 
health challenge. Potential harm from inappropriate poly-
pharmacy includes both harm to patients and also the 
additional healthcare costs that are associated with this.
Successful organisations that have transformed their 
delivery and performance have used Kotter’s 8-steps in 
combination with strong leadership that is adaptive to drive 
change.50 There is a distinction between adaptive leader-
ship and an authoritative solution to tackle problems.51 
The latter approach tends to develop short term solu-
tions to underlying problems that will often remain once 
the crisis has passed. 
Addressing complex problems like polypharmacy 
management requires change in the way that things are 
done. This can generate anxieties, which may be due 
to the fact that the activities required are different, and 
that there may be a loss of existing roles. Individuals may 
need to be challenged with the reasons why not to main-
tain the status quo. Major change often requires that 
the whole organisation needs to change and allowing 
individuals a role in a collaborative solution development 
helps to build momentum, ownership and sustainabili-
ty. Leadership needs to acknowledge that there will be 
resistance to change and that it is best to anticipate the 
barriers that this may create. Continual reflection in this 
aspect of change is important, and resolving individual’s 
anxieties is often one of the most challenging aspects 
of this type of work. 
This chapter addresses the approaches and techniques 
for successful integration of theory and practice, which 
support the process of putting the management of 
polypharmacy into practice. These techniques have been 
successfully deployed and developed across the EU 
within the SIMPATHY programme.
Change management framework
There are some important key concepts to consider 
when using change within large organisations:
• Change is not a linear process:47 although the idea of 
transformation change, moving from state A to state B, 
implies that there is a clear path between those states, 
the reality is more nuanced. Implementing a polyphar-
macy management initiative will be an adaptative and 
iterative process, and managers should be prepared to 
be flexible and take advantage of opportunities as they 
present themselves. 
• Managing change is a combination of top down and 
bottom up leadership: 52 a common criticism of change 
management models is that the emphasis is on the role 
of managers without accounting for the role of employ-
ees.53 Successful implementation of innovative polyphar-
macy management will require strategic leadership from 
managers and clinicians and policymakers.
• The up-front investment of time developing a strategy 
is time well spent:54 although taking the time to create a 
change management strategy might seem like another 
exercise in bureaucracy or waste of valuable employee 
time, as with systems thinking, the development of a plan 
will help both managers and clinicians anticipate and 
plan for implementation challenges.
Change management:  
the case of Catalonia
When designing a regional multidisciplinary model 
to address polypharmacy in older patients, the 
directors of pharmacy and medicine began by  
creating a common vision to apply within a single 
hospital. Success was dependent on both empow-
ering clinical leaders within their departments to 
take the lead on implementation, and on gaining 
support from the hospital Chief Executive Officer 
who could influence diffusion of the model to inter-
mediate care facilities and nursing homes within the 
region. Leadership at all levels is helping support 
the expansion of the model throughout the region.
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Change management:  
the case of Scotland
In Scotland, local clinical leadership developed the 
ideas and concepts creating the sense of urgency 
and provided the data to illustrate the wins from 
implementing the programme locally at primary 
care practice level. Local managers then worked 
to adopt the policy at a regional level. Further work 
was undertaken to collaborate with clinicians 
and policymakers to scale up the programme for 
national implementation. This synergy between 
frontline clinicians, managers and government was 
crucial to successful implementation and roll out. 
Getting ready for change
#1 Choosing a model
It is not essential that managers know all the details of 
various change management models, but it is benefi-
cial for them to identify where they are in the change 
management process and work with a model. The table 
below describes some general categories of change to 
consider.54 Kotter’s 8-step process for leading change has 
been integrated with these general change categories.50 
A change management framework can be used as a tool 
for both planning and progress evaluation, by reflecting on 
the different steps of a specific implementation process. 
Reviews of change management strategies, with guides 
on selecting and applying specific change management 
tools tailored to a particular organisation’s needs have 
been conducted for both the Canadian health systems 
and the National Health Service in England.47,52
Stages of 
change
Questions for managers Kotter’s 8-Step Change Model 
Getting ready 
for change
What external factors will influence this 
change?
Who are the stakeholders and who  
can I partner with to create synergies?
Is my organisation and staff ready?
Step 1. Create a sense of urgency
Step 2. Build a guiding coalition
Implementing 
change
What is our vision? How will we know when 
we’ve achieved it?
What barriers (technology, personnel, budget) 
might slow the change?
What data are we already collecting that  
can be used to demonstrate impact?
Step 3. Develop a strategic vision  
and initiatives
Step 4. Enlist a volunteer army
Step 5. Enable action by removing barriers




What data will we need to scale up? 
What new resources will we need  
to spread change?
Step 7. Sustain acceleration
How will we continuously monitor?
How will we recognise and celebrate 
successes?
What mechanisms do we have 
(contracts, pay for performance)  
that can help institute this change? 
Step 8. Institute change by anchoring new 
approach in the culture
Stages of Change and Kotters 8 step model
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The Kotter 8-step process is a core tool which can enable 
a healthcare organisation to analyse their existing polyp-
harmacy management programme and identify the stage 
of development in order to inform the next steps.50 Rec-
ognised as identifying important elements of organisa-
tional change, the model is based around a clear vision, 
good communication, empowering employees, leading 
by example and celebrating success. An important 
principle of the model is that it is most successful when 
used for continuous improvement, where leadership 
will support iterative changes and testing of delivery 
models. SIMPATHY demonstrates how the Kotter 8-step 
process can be used to successfully implement a polyp-
harmacy management programme.11
Application of the Kotter 8-step in transforming change in polypharmacy management:
1 Establishing a sense of urgency
Communicating to stakeholders the need to change current ways of reviewing medica-
tion to benefit patient care, improvement in patient safety and outcomes from medicines. 
Examining other projects that are developing and whether they pose a threat to the de-
velopment of the framework. Existing projects may focus on cost efficiencies rather than 
on patient safety due to budgetary pressures.
2 Forming a powerful guiding coalition
A project group is assembled including both primary and secondary care clinicians made 
up of doctors, pharmacists and geriatricians and long-term conditions collaborative 
leads locally and nationally. Have discussions about working together to inform work of 
medical, pharmacy and public health directors, both locally and nationally.
3 Creating a vision
A vision is created as to what the project might achieve for patient care and for the 
healthcare provider. Project plan outlines strategies for achieving the vision.
4 Communicating the vision
Share this in written communication and have face to face dialogue with people both 
locally and nationally.
5 Empowering others to act on the vision
Looking at the obstacles to change, the biggest one will be ownership, so provide feed-
back and adaptation of the protocol, e.g. link with anticipatory care plans.
6 Planning for and creating short-term wins
To gather data and provide feedback within a relatively short space of time after review 
framework is piloted. Share data from pilots and use to build the business case. Break 
the project down into smaller tasks so that results can be seen and shared, e.g. design of 
guidance for review.
7 Consolidating improvements and producing still more change
Engage with individuals that might influence change in policy to adopt the vision. Transfer 
of project to other areas to reinvigorate the project, e.g. running project in another locality 
and other health care providers.
8 Institutionalising new approaches
Sharing of benefits of the new process to the organisation, e.g. reduced admissions and 
improved patient care. Adoption of project into nationally delivered service development, 
e.g. sharing outcomes with local and national leads on service development.
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Normalization process theory (NPT) can also be used, 
predominantly as a research framework, to support the 
evaluation and implementation of complex interventions, 
such as healthcare.55 It studies what people do (action) 
rather than how they feel about what they do (attitudes), 
or what they say they are going to do (intentions). NPT 
helps to understand complex interventions by study-
ing how people make sense (coherence), engage with 
(cognitive participation), act in (collective action) and 




Leadership is a core element in change management 
and needs to be present at different organisational levels. 
Within healthcare, there is a need for strategic, political, 
managerial and clinical leadership at a national, regional 
and local level. Throughout the change process, ongoing 
work needs to be done to ensure that as many opinion 
leaders in clinical and management roles feel they are in-
volved and have personal investment in the programme. 
This helps to recruit the programme champions, who are 
essential to driving change within all levels.
 
“Crucial to the move from theory to practice was 
the early engagement of clinicians and operational 
leaders given the need to ensure that the strategy 
was felt to be ‘owned’ by the country as a whole 
rather than imposed from one area to another”.11 
When implementing a programme at scale, it is essential 
to ensure that there is both clinical and political leadership. 
#3 Assessing the scenario
 
Identification of key stakeholders and potential partners 
are important first steps to consider for any polypharmacy 
management programme. The importance of creating multi-
disciplinary leadership teams has been reported in case 
studies, and also endorsed by participants in the Delphi 
study.13 The combination of healthcare professionals, man-
agerial staff and policymakers creates the ideal coalition in 
charge of a new polypharmacy management programme. 
It is also important to include the patient when designing 
public services and including the patient representation in 
the initial guiding coalition will ensure and maintain a focus 
on patient empowerment and centeredness.56
Identifying the internal and external factors that will 
influence strategic choices is also an important early 
step. These factors can be assessed using the political, 
economic, cocial, technological, environmental and 
legal (PESTEL) framework and strengths, weaknesses, 
opportunities and threat (SWOT) analyses.57
In SIMPATHY the PESTEL domains have been adapted 
in order to specifically address the factors which are rele-
vant to polypharmacy management. The purpose of the 
PESTEL is two-fold:
 
• To systematically examine the external environment 
in which the project exists in order to detect the fac-
tors which most impinge upon it. The aim is to capture 
the impact of these factors on polypharmacy not only 
today but also in the future, by 2030.
• To future-proof polypharmacy management plans 
by helping anticipate external factors that may  
potentially derail a polypharmacy management pro-
gramme, and ensuring a robust strategy is in place. 
SWOT analysis is a supporting strategic tool that focuses 
not only on the external but also on the internal envi-
ronment. The results of these analyses cannot be seen 
as stand-alone and should be linked to implications for 
organisational action. Polypharmacy management-spe-
cific PESTEL framework and examples of SWOT analyses 




Benchmarking data can offer important insights into 
building change management programme plans. The 
SIMPATHY benchmarking survey data identifies con-
trasts between countries in terms of the stakeholders 
and teams recommended to lead and be involved in 
polypharmacy management.12
For example, the reported professionals delivering 
polypharmacy management programmes in Belgium, the 
Netherlands, Spain, Sweden and the UK are predominant-
ly pharmacists (80% of programmes). However, when 
stakeholders are asked who should be delivering pro-
grammes then a discrepancy is identified between actual 
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Physicians and nurses are currently involved in 50% and 
22% respectively, of programmes. The view of stakehold-
ers is that this should be 73% and 39% respectively. Only 
Belgium and the UK indicating that pharmacists should 
have a greater role than physicians.
The motivation for professionals to provide effective 
polypharmacy management showed wide variation 
between countries, where overall financial incentives 
were reported as the most frequent motivation, while in 
Greece, Sweden and the UK legal or contractual respon-
sibilities were a more frequently reported driver. 
Significantly, more than 90% of the respondents who 
had data on a programme, reported a positive effect on 
healthcare professionals’ satisfaction in providing the 
programme.
Where programmes existed the main aim was to improve 
patient safety by reducing medication errors and to 
reduce hospitalisations due to adverse drug reactions. In 
terms of infrastructure and systems to support manage-
ment of polypharmacy less than 4% reported current 
ICT systems as being sufficient, while more than 40% 
reported ICT as not being fit-for-purpose. 
Although the number of patient and public participants 
in the survey was limited, where programmes had data 
on patient satisfaction, 100% of them reported a positive 
effect. The majority (85%) of patients and public report-
ed that they or those they cared for would benefit from 
support to manage multiple medicines.
Benchmarking will enable countries to map out their own 
ambitions to deliver a programme by 2030. An example of 
the SIMPATHY vision routemap is shown on page 44. The 
time frame has been extended from 2025 to 2030 after 
reflection on comments made in both the benchmarking 
survey and the Delphi.13
 
 
Key questions for benchmarking and subsequent 
action:
1. State the structure – does your programme cover 
an institution, region or nation?
2. What population will you cover?
3. How will your programme look by 2030?
4. Do you have a change management plan? Have 
you done a PESTEL, SWOT and economic analysis? 
Have you mapped against Kotter’s 8-step process?
5. Does your programme address patient safety 
and improving health outcomes?
6. Are you delivering through multidisciplinary 
teams?
7. Does your review process involve the patient?
8. Do you have indicators to monitor implementa-
tion, economic benefits and patient outcomes?
Implementing change
#5 Setting the vision
A crucial early step in Kotter’s process involves creating 
and sharing a strategic vision. The importance of this was 
also something endorsed by experts in the SIMPATHY  
Delphi study.13 The strategic vision helps steer the effort 
both at management and clinician levels. Ideally, have a 
very clear picture of what you are trying to deliver and make 
sure this includes: what; by how much; when; and by whom. 
Case studies with a clear vision were found to be the most 
successful in implementing polypharmacy programmes. 
The SIMPATHY project has tested and developed a range of 
tools which can be used to support leaders in planning for 
and implementing changes in polypharmacy management. 
Using Kotter’s framework these tools can be referenced and 
deployed at key steps in the change management cycle.
“Communicating the vision became vital to making 
sure that the team was motivated and able to  
champion the programme of care. One of the initial 
goals was the establishment of a momentum to  
ensure that barriers to the successful implemen-
tation of the programme were either removed or 






















































































































































































































































1 Establish a sense of urgency x x x x x
2 Form a powerful coalition x x x x
3 Create a vision x x x x x
4 Communicate the vision x x
5 Empower others x x
6 Plan for and create short-term wins x x x x
7 Consolidate improvements x x x x
8 Institutionalise change x x x x
SIMPATHY toolkit cross-reference table
#6 Creating guidelines
The literature review identified that there are guidance 
documents available relating to the management of 
polypharmacy in only 5 of the 28 EU countries. Only the 
guidance documents from Scotland, the Netherlands and 
Germany score the maximum on the AGREE II-GRS crite-
ria for quality.25 Within Scotland, the development of the 
guidance was essential to provide the training, evidence 
and support that the clinicians needed for the implemen-
tation of medication reviews to manage multiple morbid-
ities. Through this, a powerful coalition was built as well 
as the support for political and economic case.
“Not all EU countries have the potential, experience 
and resources to develop their own national or re-
gional evidence based guidelines. Better sharing of 
information, experience, and effective collaboration 
could be cost effective solution to this”.13
#7 Training the workforce
Education at an undergraduate and postgraduate level is es-
sential for translation from theory into practice. Case studies 
have shown that education is critical for the successful im-
plementation of a polypharmacy programme, but university 
training to specifically address this field is lacking in many 
EU countries.10 In countries with successful programmes, 
postgraduate training has been a key development facili-
tator. EU experts are in agreement that there is a need for 
both undergraduate and continuing professional develop-
ment in polypharmacy management to ensure that change 
is both sustained and embedded into daily practice.13
 
Education also helps to shape professional culture. With 
consensus that multidisciplinary teams are an integral part 
of polypharmacy management, promoting collaborative 
working to develop productive professional personal rela-
tionships needs to be a focal point in the workforce training.
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Vision slides and video
The SIMPATHY vision slides are offered for use 
by any agent of change management seeking to 
address improvements in management of polyp-
harmacy. The slides can be downloaded from www.
simpathy.eu/resources/change-management, 
where a video explains the thoughts behind each 
slide. The slides are fully editable to enable the 
specific context of the initiative in different organi-
sational, regional and national settings to be edited 
or added. These slides offer material and ideas for 
developing and communicating the vision for poly-
pharmacy management.
Guidance document details Country of origin
Scottish Government Model of Care Polypharmacy Working Group. 
Polypharmacy Guidance (2nd edition). March 2015.32
Scotland
Bergert FW, Braun M, Ehrenthal K, et al. Recommendations for treating  
adult and geriatric patients on multimedication, 2014.58
Germany
Verenso. Multidisciplinaire richtlijn diabetes bij kwetsbare ouderen.  
Utrecht: Verenso. 2011.59
The Netherlands
Polypharmacy management guidance documents that scored maximum on the AGREE-II GRS
Each country or organisation determines their specific 
requirements for additional university training, under-
graduate and postgraduate education, depending on 
the national or local situation. SIMPATHY suggests that 
different approaches need to be taken within different 
countries and within different contexts. For example, 
master programmes were established in the 1980’s in the 
United Kingdom to support the development and delivery 
of clinical pharmacy services in hospital.10 More recently 
polypharmacy management has been integrated into the 
curriculum of pharmacists nurses, and physicians and 
into postgraduate clinical and prescribing programmes. 
The polypharmacy management initiatives in Sweden 
have also been supported by changes in pharmacy 
education that began there in the late 20th century.10 New 
elective clinical pharmacy courses were introduced 
into the basic pharmacy curriculum. About ten years 
later, a master degree in clinical pharmacy, based on the 
Scottish clinical pharmacy model, was initiated. At the 
same time polypharmacy management was also being 
incorporated into physician training as part of the basic 
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Demographic data depicting the problem of polypharmacy, 
and its implications on the healthcare system, are key to 
creating a sense of urgency. However, data is also essen-
tial to show the outputs of polypharmacy management. 
The ability to electronically monitor prescription data and 
the ability to share electronic medical records between 
institutions were identified in the SIMPATHY case studies 
as important features that can support implementation.10 
Findings also show that clear quality indicators and meas-
ures of polypharmacy are critical, both for the development 
of the management programme, and for the ongoing 
monitoring for evidence of success. This view was also 
endorsed by the Delphi survey participants.11,13
The table on page 49 provides example indicators 
currently in use in Catalonia (Spain), Scotland (United 
Kingdom), and Sweden.
In the SIMPATHY case studies, patient data was used  
for risk stratification to help identify patients most in 
need of an intervention, and in guiding decision making. 
Policymakers especially value local data, with an empha-
sis on both economic and clinical outcomes. Participants 
in both the SIMPATHY case studies and Delphi noted that, 
although economic data is important, clinical outcomes 
are the primary drivers for most stakeholders. As soon 
as clinical results from pilot studies are available, an 
economic analysis can be made to estimate potential 
benefits associated with carrying out the programme. 
To make such an analysis for programmes in which the 
performance of medication reviews plays a central role, 
the SIMPATHY economic analysis tool can be used. The 
tool is available on the SIMPATHY web site.







Chamber of Pharmacy, 
Lower Saxony 
Two day in person and four month 
practical training with tutor supervision 
(ATHInA)
Catalonia, Spain Primary care CatSalut (public 
insurer in Catalonia, 
Spain)
In person and online case based  
training in managing patients with 
complex chronic disease
Uppsala, Sweden Hospital and primary 
care
Uppsala University Master programme in clinical pharmacy 
for graduated pharmacists
Scotland Hospital, intermediate 
care, primary care
NHS Education for 
Scotland
Multiple courses in advanced pharmacy 
practice ranging from pre-registration 
training to independent prescribing
Northern Ireland Hospital, intermediate 
care, primary care
Northern Ireland 
Centre for Pharmacy 
Learning and 
Development
Multiple courses in advanced 
pharmacy practice ranging from  
pre-registration training to 
independent prescribing




Catalonia General pharmacy indicators
• Number of prescriptions per user
• Average cost of prescription per patient
Polypharmacy management specific indicators
• % of patients with polypharmacya
• Index of prescription qualityb
Pharmacy cost indicators
• Cost per patient treated with ACEI or ARB
• Cost per patient treated with cholesterol lowering agents
• Cost per patient treated with antidepressants
Scotland Standard polypharmacy indicator
• 10 or more BNF paragraphs dispensed in a 6 month period with at least one high-risk medicine
High risk prescribing indicators:
• Older person (>=75 years) prescribed an antipsychotic drug
• Older person (>=65 years) currently taking an ACE inhibitor/angiotensin receptor blocker 
and a diuretic, who is prescribed an NSAID (the ‘triple whammy’)
• Older person (>=75 years) prescribed an NSAID without gastroprotection
• Older person (>=65 years) currently taking either aspirin or clopidogrel who is prescribed  
an NSAID without gastroprotection
• Current anticoagulant user prescribed an NSAID without gastroprotection
• Current anticoagulant user prescribed aspirin or clopidogrel without gastroprotection
Sweden Drug-specific indicatorsc
• Medicines that should be avoided unless a specific reason exists: long-acting 
benzodiazepines, medicines with significant anticholinergic effects, tramadol.
Diagnosis specific indicatorsc
• COPD: irrational use, oral ß-2 receptor agonist; hazardous use, non-selective ß-blocker.
Key: a) defined as 18 or more different active ingredients dispensed in one month, b) composite index to evaluate overall prescription quality,  
c) Only one drug specific indicator and one diagnosis specific indicator are presented in this table. There are 20 indicators with 63 items in total.
Polypharmacy management indicators
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SIMPATHY economic analysis tool
The goal of the SIMPATHY economic analysis toola is 
to provide a high-level analysis of the economic costs 
and benefits associated with carrying out polyphar-
macy reviews.
 
The analysis follows a top-down approach and esti-
mates maximum costs and benefits associated with 
activity. Activity is driven by the selected population 
for whom reviews are intended to be carried out. 
Costs of reviews are based on the resource (staff) cost 
of carrying out a review, net of any potential review 
charge. The direct potential financial benefit of reviews 
will consist of the net reduction in medicines prescribed, 
and associated expenditure. Potential indirect benefits 
(non-cash releasing) centre around potentially avoided 
adverse drug reactions (ADRs), preventable hospital 
admissions associated with these ADRs, and the asso-
ciated number of hospital bed days avoided.
Ultimately, the tool is intended to add to the package 
of change management tools by offering a bespoke 
analysis of the micro-economic impacts, the costs 
and benefits of introducing and carrying out reviews. 
It is thought that this will give a broad overview around 
resource needs and potential benefits to interested 
users the cost of carrying out a review, net of any 
potential review charge. The direct potential financial 
benefit of reviews will consist of the net reduction 
in drugs prescribed, and associated expenditure. 
Potential indirect benefits (non-cash releasing) centre 
around potentially avoided ADRs, preventable hospital 
admissions associated with these ADRs, and the asso-






Regulation and governance help to institutionalise  
polypharmacy management as a priority, establishing 
minimum standards, holding providers accountable,  
and enabling enforcement actions, if necessary. The 
SIMPATHY case studies have shown that government 
policies and legislation specifically related to polyphar-
macy facilitate implementation, but are not essential to 
start a new or pilot programme, and Delphi participants 
confirmed the importance of integrated polypharmacy 
management into health policies.10 Most SIMPATHY pro-
grammes originated in health systems where local gov-
ernment exercise some control over policy and practice 
decisions. Specifically, the existence of local governance 
models with power to make policy, reallocate resources 
and create new practice models seemed to play a role in 
the emergence of programmes.
“A key political strength has been the recognition 
of appropriate polypharmacy work as a core part 
of the governments clinical strategy and realistic 
medicines agenda, and its inclusion as a key prior-
ity area […] supported by the NHS Scotland Chief 
Executive and the Cabinet Secretary for Health”.  
– an example from Scotland.11
Payment models also need to be realigned with the 
goals and objectives of new clinical activities, although 
how exactly this should be done will depend on the local 
situation. Some strategies that have been successful 
in integrating polypharmacy management into clinical 
practice include creating contractual requirements 
or instituting pay for performance objectives tied to 
medication reviews. New clinical positions specific to 
medication reviews and polypharmacy have also been 
created. SIMPATHY shows how in Sweden support was 
provided by the government and professional bodies for 
short term demonstration projects, and this funding was 
used to establish the clinical and economic impact of the 
programme, which resulted in new positions for clinical 
pharmacists. In Scotland, the government started to 
invest in ensuring all primary care centres had a pharma-
cist that worked as part of the multidisciplinary team to 
deliver polypharmacy reviews.
Identifying already existing regulations relating to poly-
pharmacy management can act as a foundation to build 
a formal programme. For example, work regulations 
in Germany stating that medication reviews are within 
the scope of the practice of pharmacists facilitated the 
development of a programme at regional level.11 In Poland, 
a policy that relates to polypharmacy management is an 
Act on Pharmaceutical Chambers [Act of 19.04.1991]. It 
states that pharmacists should “implement pharmaceu-
tical care based on a documented process, in which the 
pharmacist, cooperating with patient and physician and if 
needed other healthcare professionals, takes care of prop-
er pharmacotherapy in order to improve the patient’s quality 
of life”.11 Both of these countries have used this legislation 
to implement medication management activities in com-
munity pharmacies.
#10 Evaluating the programme
In this phase, it is helpful to understand how healthcare 
professionals have integrated the work as part of routine 
practice by making use of normalization process theory 
(NPT).55 For example, one challenge of a new programme 
is the changes required in time management to integrate 
a new service. By applying NPT construct of collective 
action, the SIMPATHY case studies clearly showed that 
polypharmacy management cannot be added on top of 
existing work. Redesign of workflow is essential.10 When 
you are planning a process evaluation, NPT may help you 
to structure this evaluation.55 NPT will encourage you 
to focus on the range of people, situations, times and 
places that are involved in all aspects of enacting that 
process of providing the intervention (or comparator). 
NPT can help inform, guide or structure your emerging 
interpretations, conclusions and recommendations.

EU collaboration for global 
patient safety challenge
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In order to address appropriate polypharmacy, groups 
that are interested need to work in partnership to avoid 
duplication of efforts, and this needs to be coordinated 
across policy and practice and include all stakeholders, 
in particular patients and the public. Patients and the 
public should be integral to groups that develop policy 
and tools for implementation, and act as ambassadors to 
raise the issue of polypharmacy among low and middle 
income countries. 
In March 2017, the WHO launched the global patient safety 
challenge to improve medication safety, and identified 
polypharmacy as a flagship area to address across all 
care settings, due to the potential patient harm from inap-
propriate polypharmacy. The tools developed to support 
implementation of a polypharmacy programme can be 
used by low to high income countries across Europe. The 
challenges that Europe faces in managing polypharmacy 
are found globally.61 The EU should take a leadership role 
in the implementation of the global challenge to improve 
medication safety and polypharmacy.
Patient adherence with multiple medications is 50% for 
those taking 4 or more medicines. Through collabora-
tion with the SIMPATHY project, addressing appropriate 
polypharmacy will be undertaken as part of the Euro-
pean Society for Patient Adherence, COMPliance and 
persistence (ESPACOMP) and this will be achieved on an 
ongoing basis through their work programme. 
The SIMPATHY routemap illustrates the key actions that 
would need to be undertaken to ensure that patients 
across Europe are not exposed to inappropriate polyp-
harmacy. Addressing this patient safety issue would also 
realise economic benefits, to help deliver the triple aim  
of potentially 4.23 billion euros across the EU. 
In order to raise the awareness of the impact of polyp-
harmacy on patient safety, the SIMPATHY project has 
provided the leadership to establish a special interest 
group with the International Foundation on Integrated 
Care (IFIC) on appropriate polypharmacy and complex 
care. Policymakers need to be integral to this work in  
order that policy helps determine the role of health pro-
fessionals for medicines safety and the implementation 
of programmes across health and care systems. Adopting 
a systems approach will help to ensure that appropriate 
polypharmacy is considered and addressed when pre-
scribing new medicines, reviewing treatment plans, and 
at care interfaces. This will support the appropriate use 
of medicines for all patients with multiple morbidities.
Summary of Recommendations
1. Use a systems approach that has multidisciplinary 
clinical and policy leadership
Polices should be supported with implementation plans 
that will enable delivery of polypharmacy reviews at scale, 
and in order to build capacity that is sustainable, use the 
multidisciplinary team to deliver. Barriers to implemen-
tation such as a lack of interprofessional working and 
training need to be addressed in order to enable this to be 
delivered. Health professionals need to work in multidisci-
plinary teams to deliver optimum outcomes for patients. 
Promoting appropriate polypharmacy at the point of med-
icines initiation or during medicines review is therefore of 
the upmost importance and deserves greater attention.
When patients are admitted to hospital, records should 
routinely monitor if an adverse drug reaction or if a  
medication has led to the symptoms that has caused 
the admission. Health and care providers need to have 
monitoring systems in place that capture data that re-
cord where medication harm is the cause of admissions 
to hospital so that improvement can be measured and 
learning from feedback can take place. 
2. Nurture a culture that encourages and prioritises the 
safety and quality of prescribing 
Address the safety culture to enable health care profes-
sionals to discuss issues of polypharmacy, especially 
where they are not responsible for prescribing, but also 
so that patients feel that it is safe to ask questions. 
Patients should expect to have their medicines re-
viewed and patients should expect integrated care and 
a systems approach so that decisions made about their 
medicines are communicated to all relevant parties 
across the patient pathway. 
3. Ensure that patients are integral to the decisions 
made about their medicines and are empowered  
and supported to do so 
Raising patient awareness about the problems of 
polypharmacy and non-adherence and how to prevent 
harm from medicine related side effects is essential. 
Patients should hold a record of medication that they 
take and share at each care interface to allow clinicians 
to consider impact of additional medication or stopping 
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treatment. This can be in either paper or electronic form 
so that it is accessible for patients in low and middle 
income countries as well.
Patients need to be provided with information, and tools 
need to be developed that enable patients to ask ques-
tions and understand how to make decisions regarding 
management of their long-term conditions. Information 
should be consistent across all parts of the healthcare 
system. Patients should have access to mobile apps and 
tools that help them understand appropriate polypharma-
cy, and enable them to be active participants in medica-
tion reviews. An example of a patient card, known as sick 
day rule guidance is shown above, which is also available 
on a patient polypharmacy app where the patient and 
clinician can agree tailored guidance for the individual.
4. Use of data to drive change 
Data should be used where possible to monitor and evaluate 
any programmes. Polypharmacy measures and indicators 
that address review of prescribing that has the potential to 
cause harm should be developed where country systems 
allow, with learning and sharing of the information.
Where possible, there should be electronic sharing of 
prescribing information across the interface. In many 
countries, this is not possible and does not exist in either 
paper or electronic form.
5. Adopt an evidenced based approach with a bias 
towards action
Safety is a major concern in modern healthcare. The  
SIMPATHY literature review confirmed that there is  
evidence to support the principle that medication 
reviews reduce inappropriate polypharmacy.23 Recent 
research has begun to show improvement in outcomes 
including hospital admission.24 The literature review 
identified that there are guidance documents available 
relating to the management of polypharmacy in only 5 of 
the 28 EU countries, with only the guidance documents 
from Scotland, the Netherlands and Germany scoring 
the maximum on the AGREE II-GRS criteria for quality.25 
There remains an evidence gap, whilst research catch-
es up with this fundamental change in healthcare. The 
SIMPATHY literature review supports the principle that it 
is important to adopt an evidence based approach, but 
with a bias towards action where the evidence is limited.
6. Utilise, develop and share tools to support 
implementation
Polypharmacy management touches multiple aspects of 
the health and care systems and is ideally team-based 
and patient-centred. Embedding polypharmacy man-
agement into integrated care initiatives will help create 
synergies with ongoing activities with the aim to prevent 
inappropriate polypharmacy. Polypharmacy management 
initiatives are complex and require strong leadership 
and management. Employing a change management 
strategy when designing a polypharmacy management 
initiative can help maximise the odds of successful im-
plementation. All healthcare professionals need to follow 
a standard set of principles when reviewing medication 
and involve the patients and their carer’s in the reviews 
by asking ‘what matters to you?’ in order to take a patient 
centred approach. Tools that deliver this should be shared 
across all countries to enable this to be achieved. 
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Use of existing guidance and mobile apps that  
incorporate the guidelines and key steps should be 
shared to spread good practice. Scotish Polypharmacy 
app launched in April 2016 can be found at  
http://www.polypharmacy.scot.nhs.uk/
This recommendations can be sumarised into short, 
medium and long term. 
Short term
• Raise awareness about the problems with polypharmacy 
with healthcare professionals and patient groups
• Launch of Polypharmacy Special Interest Group (SIG)  
at the International Foundation on Integrated Care
• EU adopt leadership role in the WHO global patient  
safety medication challenge
• Share change management tools to support imple-
mentation of polypharmacy programmes across Europe, 
including benchmarking tools
• Share tools to undertake polypharmacy reviews across 
Europe for clinicians and for patients that enable them  
to take an active role in their care
• Tools available to organisations at local, regional and 
national level to enable leaders to establish and sustain  
a safety culture
Medium term
• Ensure appropriate polypharmacy is integral to care 
pathways for patients with multiple morbidities 
• Ensure appropriate polypharmacy is integral to medical, 
pharmacy and nursing undergraduate and postgraduate 
teaching
• Develop indicators for use to demonstrate improvement 
in polypharmacy management and patient outcomes
• Review of policy to enable multidisciplinary working
Long term
• All countries across the EU implement programmes 
 to address polypharmacy
• All patients at risk of harm from medication have access 
to polypharmacy reviews
• When patients have a hospital admission caused by  
an adverse effect due to medication, this should be  
captured in the electronic data base
• Ensure technology is safe and optimised to support 
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